On the Horizon: Asciminib, a New Drug for Treating R/R CML On the Horizon: Asciminib, a New Drug for Treating R/R CML

A first-in-class STAMP inhibitor, asciminib, shows better efficacy than bosutinib in patients with relapsed/refractory chronic myeloid leukemia in the chronic phase.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news